In the oncology field, particularly for patients with NSCLC (NSCLC), osimertinib plus alectinib has emerged as a pioneering combination treatment.An creative treatment method, which combines the efficacy of osimertinib, a 3rd generation EGFR TKI (TKI), and alectinib, a strong ALK TKI, has been developed.clinical studies have shown encouraging outcomes with the synergistic impact of this combination, offering fresh hope for patients fighting advanced NSCLC (NSCLC).EGFR TK, often mutated NSCLC (NSCLC) patients, is inhibited by osimertinib, which in turn prevents the proliferation and metastasis of tumor cells.Alternatively, alectinib targets ALK TK,…
